Nuvo Pharmaceuticals Inc NRIFF

news

[golfclub2]

New Improved Dosing Approved for Pennsaid

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ -- Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, and Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced that Health Canada has approved a new dosing regimen for Pennsaid(R) (topical diclofenac). Paladin sells and markets Pennsaid in Canada, having acquired exclusive Canadian Pennsaid rights from Nuvo in August 2005.

The new dosing regimen of Pennsaid(R) will be 50 drops per knee, 3 times a day, as an alternative to the existing approved dosing regimen of 40 drops per knee, 4 times a day. Pennsaid(R) is now the only topical NSAID approved in Canada with this new improved dosing regimen. Pennsaid had Canadian sales of $10.6 million last year and has been sold in Canada since May 2003.

"Pennsaid(R) is a proven effective treatment for Osteoarthritis of the knee," said Dr. Philip Baer, a Rheumatologist practicing in Ontario. "The newly approved dosing regimen of 50 drops TID (three-times-per-day) will make it easier for patients to use Pennsaid(R) to manage their pain, as compared to applying 40 drops QID (four-times-per-day). TID dosing can improve patient compliance, which is one of the most important factors in ensuring effective pain relief."

"The new improved dosing regimen of Pennsaid(R) is a significant clinical advantage," said Henrich Guntermann, Nuvo's President and CEO. "We are eager to replicate Pennsaid's Canadian success in the U.S. market and continue to work diligently on obtaining U.S. FDA approval."